Annovis Bio
NYSE:ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Bellicum Pharmaceuticals
NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Hoth Therapeutics
NASDAQ:HOTHHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
Q BioMed
OTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.
Sunesis Pharmaceuticals
NASDAQ:SNSSSunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.